{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T14:49:55Z","timestamp":1781707795568,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002920","name":"University Grants Committee Research Grants Council","doi-asserted-by":"publisher","award":["T11-705\/21-N"],"award-info":[{"award-number":["T11-705\/21-N"]}],"id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","award":["NUHSRO\/2023\/018\/startup\/10"],"award-info":[{"award-number":["NUHSRO\/2023\/018\/startup\/10"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020765","name":"Guangdong University of Technology Laboratory of Low-Dimensional Materials and Energy Storage Devices","doi-asserted-by":"publisher","award":["EKPG22-30-6"],"award-info":[{"award-number":["EKPG22-30-6"]}],"id":[{"id":"10.13039\/100020765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021B1515130005"],"award-info":[{"award-number":["2021B1515130005"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["PREPARE-CS1-2023-011"],"award-info":[{"award-number":["PREPARE-CS1-2023-011"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["PREPARE-CS1-2022-003"],"award-info":[{"award-number":["PREPARE-CS1-2022-003"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005407","name":"Hong Kong Food and Health Bureau","doi-asserted-by":"publisher","award":["COVID1903003"],"award-info":[{"award-number":["COVID1903003"]}],"id":[{"id":"10.13039\/501100005407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022720","name":"Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022720","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jinf.2024.106374","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:30:26Z","timestamp":1733621426000},"page":"106374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine"],"prefix":"10.1016","volume":"90","author":[{"given":"Chris Ka Pun","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Sang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9837-1413","authenticated-orcid":false,"given":"Chee Wah","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Chun","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunke","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2916-7763","authenticated-orcid":false,"given":"Yuanxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8141-6389","authenticated-orcid":false,"given":"Kwun Cheung","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-5846","authenticated-orcid":false,"given":"Ken KP","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2024.106374_bib1","unstructured":"Statement on the antigen composition of COVID-19 vaccines. \u3008https:\/\/www.who.int\/news\/item\/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines\u3009 (accessed May 28, 2024)."},{"key":"10.1016\/j.jinf.2024.106374_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e30208","article-title":"Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies","volume":"10","author":"Faraji","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.jinf.2024.106374_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev-virology-093022-013037","article-title":"The emergence and evolution of SARS-CoV-2","volume":"11","author":"Holmes","year":"2024","journal-title":"Annu Rev Virol"},{"key":"10.1016\/j.jinf.2024.106374_bib4","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106374_bib5","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106374_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","article-title":"COVID-19 vaccines: the status and perspectives in delivery points of view","volume":"170","author":"Chung","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"10.1016\/j.jinf.2024.106374_bib7","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s12985-024-02335-9","article-title":"Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-na\u00efve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4\/5) bivalent booster vaccination","volume":"21","author":"Cheng","year":"2024","journal-title":"Virol J"},{"key":"10.1016\/j.jinf.2024.106374_bib8","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"issue":"18","key":"10.1016\/j.jinf.2024.106374_bib9","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2022.27.18.2200178","article-title":"SARS-CoV-2 Omicron variant BA.2 neutralisation in sera of people with Comirnaty or CoronaVac vaccination, infection or breakthrough infection, Hong Kong, 2020 to 2022","volume":"27","author":"Cheng","year":"2022","journal-title":"Euro Surveill"},{"key":"10.1016\/j.jinf.2024.106374_bib10","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.15585\/mmwr.mm7144a3","article-title":"Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among persons aged \u226512 years \u2013 United States, August 31-October 23, 2022","volume":"71","author":"Hause","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jinf.2024.106374_bib11","unstructured":"FDA. Recommendation for the 2023\u20132024 Formula of COVID-19 vaccines in the U.S.; 2023."},{"issue":"6","key":"10.1016\/j.jinf.2024.106374_bib12","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.3201\/eid3006.240051","article-title":"Evaluating humoral immunity elicited by XBB.1.5 monovalent COVID-19 vaccine","volume":"30","author":"Nguyenla","year":"2024","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jinf.2024.106374_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chom.2024.01.014","article-title":"XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1","volume":"32","author":"Wang","year":"2024","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jinf.2024.106374_bib14","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/S1473-3099(23)00784-3","article-title":"Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals","volume":"24","author":"Kosugi","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106374_bib15","article-title":"T cells in SARS-CoV-2 infection and vaccination","volume":"10","author":"Young","year":"2022","journal-title":"Ther Adv Vaccines Immunother"},{"key":"10.1016\/j.jinf.2024.106374_bib16","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Moderbacher","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jinf.2024.106374_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jinf.2024.106374_bib18","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/S2666-5247(23)00006-X","article-title":"Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study","volume":"4","author":"Mok","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jinf.2024.106374_bib19","unstructured":"Centre for Health Protection \u2013 COVID-19 Vaccination Programme. \u3008https:\/\/www.chp.gov.hk\/en\/features\/106934.html\u3009 (accessed May 28, 2024)."},{"issue":"12","key":"10.1016\/j.jinf.2024.106374_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jinf.2024.106374_bib21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jinf.2024.106374_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115175","article-title":"The immunostimulatory nature of mRNA lipid nanoparticles","volume":"205","author":"Sharma","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.jinf.2024.106374_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-023-00751-6","article-title":"Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability","volume":"8","author":"Zhang","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.jinf.2024.106374_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S1473-3099(22)00345-0","article-title":"Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study","volume":"22","author":"McMenamin","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106374_bib25","article-title":"BNT162b2 vaccination effectively prevents the rapid rise of SARS-CoV-2 variant B.1.1.7 in high-risk populations in Israel","volume":"2","author":"Munitz","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jinf.2024.106374_bib26","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1093\/cid\/ciab438","article-title":"The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data","volume":"74","author":"Chodick","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2024.106374_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jinf.2024.106374_bib28","unstructured":"COVID-19 Thematic Website \u2013 Together, We Fight the Virus. Archive of Statistics on Provisional Analysis on Reported Death Cases. \u3008https:\/\/www.coronavirus.gov.hk\/eng\/death_analysis.html\u3009 (accessed May 28, 2024)."},{"issue":"12","key":"10.1016\/j.jinf.2024.106374_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.40364","article-title":"Analysis of COVID-19 vaccine type and adverse effects following vaccination","volume":"4","author":"Beatty","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jinf.2024.106374_bib30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1080\/14760584.2024.2397026","article-title":"A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children","volume":"23","author":"Priddy","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jinf.2024.106374_bib31","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2024.29.25.2300585","article-title":"Association between adverse events after COVID-19 vaccination and anti-SARS-CoV-2 antibody concentrations, the Netherlands, May 2021 to November 2022: a population-based prospective cohort study","volume":"29","author":"Holwerda","year":"2024","journal-title":"Eur Surveill"},{"key":"10.1016\/j.jinf.2024.106374_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101174","article-title":"Long-term persistence of SARS-CoV-2 neutralizing antibody responses after infection and estimates of the duration of protection","volume":"41","author":"Lau","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jinf.2024.106374_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101926","article-title":"Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis","volume":"58","author":"Martin","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324003098?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324003098?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:27:03Z","timestamp":1778718423000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324003098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0163445324003098"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106374","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of safety and immunogenicity in the elderly after receiving either Comirnaty or Spikevax monovalent XBB1.5 COVID-19 vaccine","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106374"}}